S100B in schizophrenia: An update

General Physiology and Biophysics

Volumn 28, Issue , 2009, Pages

  Rothermundt, Matthias ^a   Ahn, Jan Niklas ^a   Jörgens, Silke ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Glia cells; Inflammation; S100B; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOKINE; ERYTHROPOIETIN; FLUPENTIXOL; INOSITOL; NEUROLEPTIC AGENT; PROTEIN S100B; RISPERIDONE;

ASTROCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE ASSOCIATION; GLIA CELL; HUMAN; IMMUNOCOMPETENT CELL; MICROGLIA; NEGATIVE SYNDROME; NERVE CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ASTROCYTES; BRAIN; CENTRAL NERVOUS SYSTEM; COGNITION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MODELS, GENETIC; NERVE GROWTH FACTORS; NEUROGLIA; S100 PROTEINS; SCHIZOPHRENIA;

EID: 77149137666     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Arnold S. E., Trojanowski J. Q., Gur R. E., Blackwell P., Han L.Y., Choi C. (1998): Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch. Gen. Psychiatry 55, 225-232
2. Arnold S. E. (1999): Neurodevelopmental abnormalities in schizophrenia: Insights from neuropathology. Dev. Psychopathol. 11, 439-456
3. Bayer T. A., Buslei R., Havas L., Falkai P. (1999): Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 271, 126-128
4. Bechter K., Herzog S., Richt J. A., Schüttler R. (1997): Zur Pathogenität von Borna-disease-Virus für psychiatrische und neurologische Störungen beim Menschen: Derzeitiger Forschungsstand und kritischer Kommentar. Der Nervenarzt 68, 425-430
5. Borda T., Perez Rivera R., Joensen L., Gomez R. M., Sterin-Borda L. (2002): Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J. Immunol. 168, 3667-3674
6. Brown A. S., Begg M. D., Gravenstein S., Schaefer C. A., Wyatt R. J., Bresnahan M., Babulas V. P., Susser E. S. (2004): Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 61, 774-780
7. Danos P., Schmidt A., Baumann B., Bernstein H. G., Northoff G., Stauch R., Krell D., Bogerts B.(2005): Volume and neuron number of the mediodorsal thalamic nucleus in schizophrenia: a replication study. Psychiatry Res. 140, 281-289
8. A receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 72, 1593-1599
9. DeLisi L.E. (1999): Regional brain volume change over the life-time course of schizophrenia. J. Psychiatr. Res. 33, 535-541
10. Donato R. (2003): Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 60, 540-551
11. Dong Y., Benveniste E. N. (2001): Immune function of astrocytes. GIia 36, 180-190
12. Falkai P., Honer W. G., David S., Bogerts B., Majtenyi C., Bayer T. A. (1999): No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol. Appl. Neurobiol. 25, 48-53
13. Falke E., Han L. Y., Arnold S. E. (2000): Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res. 93, 103-110
14. Gattaz W. F., Lara D. R., Elkis H., Portel L. V., Goncalves C. A., Tort A. B., Henna J., Souza D. O. (2000): Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr. Res. 43, 91-95
15. Geroldi D., Falcone C, Emanuele E. (2006): Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13, 1971-1978
16. Gur R. E., Cowell P., Turetsky B. I., Gallacher F., Cannon T., Bilker W., Gur R. C. (1998): A follow-up magnetic resonance imaging study of schizophrenia. Arch. Gen. Psychiatry 55, 145-152
17. Harrison P. J. (1999): The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122, 593-624
18. Heizmann C. W., Ackermann G. E., Galichet A. (2007): Pathologies involving the S100 proteins and RAGE. Subcell. Biochem. 45, 93-138
19. Hohoff C., Ponath G., Freitag C. M., Kästner F., Krakowitzky P., Domschke K., Koelkebeck K., Kipp F., von Eiff C., Deckert J., Rothermundt M. (2009): Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals. Am. J. Med. Genet. B: Neuropsychiatr. Genet. Epub ahead of print PMID: 19330775
20. Huang W.-J., Liu Z.-C, Wei W., Wang G-H., Wu J.-G., Zhu F. (2006): Human endogenous retroviral pol RNA and protein detected and identified in the blood of individuals with schizophrenia. Schizophr. Res 83, 193-199
21. Iwahashi K., Watanabe M., Nakamura K., Suwaki H., Ikuta K. (1997): Clinical investigation of the relationship between Borna disease virus (BDV) infection and schizophrenia in 67 patients in Japan. Acta Psychiatr. Scand. 96, 412-415
22. Jones L. B., Johnson N., Byne W. (2002): Alterations in MAP2 immunocytochemistry in areas 9 and 32 of schizophrenic prefrontal cortex. Psychiatry Res. 114, 137-148
23. Karlsson H., Bachmann S., Schroder J., McArthur J., Torrey E. F., Yolken R. H. (2001): Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 98, 4634-4639
24. Kurumaji A., Wakai T., Toru M. (1997): Decreases in peripheraltype benzodiazepine receptors in postmortem brains of chronic schizophrenics. J. Neural Transm. 104, 1361-1370
25. Licinio J., Seibyl J. P., Altemus M., Charney D. S., Krystal J. H. (1993): Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry 150, 1408-1410
26. Lara D. R., Gama C. S., Belmonte-de-Abreu P., Portela L. V. C., Goncalves C. A., Fonseca M., Hauck S., Souza D. O. (2001): Increased serum S100B protein in schizophrenia: a study in medication-free patients. J. Psychiatr. Res. 35, 11-14
27. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. (2001): Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 49, 487-499
28. Liu J., Shi Y., Tang J., Guo T., Li X., Yang Y., Chen Q., Zhao X., He G., Feng G., Gu N., Zhu S., Liu H., He L. (2005): SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem. Biophys. Res. Commun. 328, 335-341
29. Matute C., Melone M., Vallejo-Illarramendi A., Conti F. (2005): Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49, 451-455
30. McAllister C. G., van Kammen D. P., Rehn T. J., Miller A. L., Gurklis J., Kelley M. E., Yao J., Peters J. L.(1995): Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry. 152, 1291-1297
31. McGlashan T. H., Hoffman R. E. (2000): Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 57, 637-648
32. McGrath J. J., Pemberton M. R., Welham J. L., Murray, R. M. (1994): Schizophrenia and the influenza epidemics of 1954, 1957 and 1959: A southern hemisphere study. Schizophr. Res. 14, 1-8
33. Mednick S. A., Machon R. A., Huttunen M. D., Bonett D. (1988): Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 45, 189-192
34. Nikkilä H. V., Müller K., Ahokas A., Miettinen K., Rimón R., Andersson L. C. (1999): Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry 156, 1725-1729
35. Nygaard O., Langbakk B., Romner B. (1997): Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin. Chem. 43, 541-543
36. Pearlson G. D., Marsh L. (1999). Structural brain imaging in schizophrenia: A selective review. Biol. Psychiatry 46, 627-649
37. Pedersen A., Diedrich M., Kaestner F., Koelkebeck K., Ohrmann P., Ponath G., Kipp F., Abel S., Siegmund A., Suslow T., von Eiff C., Arolt V., Rothermundt M. (2008): Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 32, 1789-1792
38. Powers R. E. (1999). The neuropathology of schizophrenia. J. Neuropathol. Exp. Neurol. 58, 679-690
39. Radewicz K., Garey L. J., Gentleman S. M., Reynolds R. (2000): Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 59, 137-150
40. Rajkowska G, Miguel-Hidalgo J. J., Makkos Z., Meltzer H., Overholser J., Stockmeier C. (2002): Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 57, 127-138. Erratum in: Schizophr. Res. 60, 103
41. Rothermundt M., Arolt V., Bayer T. A. (2001a): Review of immunological and immunopathological findings in schizophrenia. Brain. Behav. Immun. 15, 319-339
42. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., Rudolf S., Wandinger K. P., Kirchner H. (2001b): Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 6, 445-449
43. Rothermundt M., Ponath G., Glaser T., Hetzel G., Arolt V. (2004): S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29, 1004-1011
44. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., Suslow T., Peters M., Kaestner F., Heindel W., Arolt V., Pfleiderer B. (2007): Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myoinositol. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 361-364
45. Ryoun Kim H., Kyung Lee M., Park D. B. (2007): Increased serum S100B protein in chronic schizophrenic patients in Korea. Clin. Chem. Lab. Med. 45, 1561-1563
46. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F. A., Falkai P. (2005): Increased serum S100B in elderly, chronic Schizophrenic patients: Negative correlation with deficit Symptoms. Schizophr. Res. 80, 305-313
47. Schroeter M. L., Abdul-Khaliq H., Frühauf S., Höhne R., Schick G, Diefenbacher A., Blasig I. E. (2003): Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr. Res. 62, 231-236
48. Schroeter M. L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I. E. (2009): Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia - original research and meta-analysis. Psychiatry Res. 167, 66-72
49. Selemon L. D., Goldman-Rakic P. S. (1999): The reduced neuropil hypothesis: A circuit based model of schizophrenia. Biol. Psychiatry 45, 17-25
50. Sham P. C., O'Callaghan E., Takei N., Murray G. K., Hare E. H., Murray R. M. (1992): Schizophrenia following prenatal exposure to influenza epidemics between 1939 and 1960. Br. J. Psychiatry 160, 461-466
51. Shenton M. E., Dickey C. C., Frumin M., McCarley R. W. (2001): A review of MRI findings in schizophrenia. Schizophr. Res. 49, 1-52
52. Steiner J., Bielau H., Bernstein H. G., Bogerts B., Wunderlich M. T. (2006a): Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J. Neurol. Neurosurg. Psychiatry 77, 1284-1287
53. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H. G., Bogerts B. (2006b): Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 112, 305-316
54. Steiner J., Bernstein H. G., Bielau H., Farkas N., Winter J., Dobrowolny H., Brisch R., Gos T., Mawrin C., Myint A. M., Bogerts B. (2008a): S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J. Psychiatr. Res. 42, 868-876
55. Steiner J., Walter M., Wunderlich M. T., Bernstein H. G., Panteli B., Brauner M., Jacobs R., Gos T., Rothermundt M., Bogerts B. (2008b): A new pathophysiological aspect of S100B in schizophrenia: Potential regulation of S100B by its scavenger soluble RAGE. Biol. Psychiatry, Epub ahead of print PMID: 19103440
56. Sugai T., Kawamura M., Iritani S., Araki K., Makifuchi T, Imai C., Nakamura R., Kakita A., Takahashi H., Nawa H. (2004): Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann. N. Y. Acad. Sci. 1025, 84-91
57. Tkachev D., Mimmack M. L., Ryan M. M., Wayland M., Freeman T, Jones P. B., Starkey M., Webster M. J., Yolken R. H., Bahn S. (2003): Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362, 798-805
58. Togo T, Akiyama H. I., Kondo H., Ikeda K., Kato M., Iseki E, Kosaka K. (2000): Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res. 885, 117-121
59. van Berckel B. B. R., Caspers E., Cahn W., Lammertsma A., Kahn R. (2005): Microglia activation in schizophrenia: an (R)-[11C]-PK11195 positron emission tomography study (abstract from the 2005 international congress on schizophrenia research, Savannah, Georgia). Schizophr. Bull. 31, 448
60. van Berckel B. N., Bossong M. G, Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A. D., Cahn W., Lammertsma A. A., Kahn R. S. (2008): Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C] PK11195 positron emission tomography study. Biol. Psychiatry 64, 820-822
61. Webster M. J., Knable M. B., Johnston-Wilson N., Nagata K., Inagaki M., Yolken R. H. (2001): Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav. Immun. 15, 388-400
62. Wierzba-Bobrowicz T., Lewandowska E., Lechowicz W., Stepień T., Pasennik E. (2005): Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol. 43, 81-89
63. Wiesmann M., Wandinger K. P., Missler U., Eckhoff D., Rothermundt M., Arolt V., Kirchner H. (1999): Elevated plasma levels of S-100b protein in schizophrenic patients. Biol. Psychiatry 45, 1508-1511
64. Wright P., Gill M., Murray R. M. (1993): Schizophrenia: genetics and the maternal immune response to viral infection. Am. J. Med. Genet. 48, 40-46
65. Yolken R. H., Karlsson H., Yee R, Johnston-Wilson N. L., Torrey E. F. (2000): Endogenous retroviruses and schizophrenia. Brain Res. Rev. 31, 193-199